Effectiveness of meningococcal vaccines at reducing invasive meningococcal disease and pharyngeal Neisseria meningitidis carriage: A systematic review and meta-analysis

2020 ◽  
Author(s):  
Mark McMillan ◽  
Abira Chandrakumar ◽  
Hua Lin Rachael Wang ◽  
Michelle Clarke ◽  
Thomas R Sullivan ◽  
...  
Keyword(s):  
Neisseria Meningitidis ◽  
Meningococcal Disease ◽  
Incidence Rate Ratio ◽  
Meta Analysis ◽  
Membrane Vesicle ◽  
Invasive Meningococcal Disease ◽  
Meningococcal Vaccines ◽  
Unpublished Studies ◽  
Group B ◽  
4Cmenb Vaccine

Abstract Background Invasive meningococcal disease (IMD), caused by Neisseria meningitidis, leads to significant morbidity and mortality worldwide. This review aimed to establish the effectiveness of meningococcal vaccines at preventing IMD and N. meningitidis pharyngeal carriage. Methods A search within PubMed, Embase, Scopus, and unpublished studies up to 1st February 2020 was conducted. Results After removal of duplicates, 8565 were screened and 28 studies included. Protection was provided by meningococcal C vaccines for group C IMD (odds ratio (OR) 0·13 [95% CI, 0·07-0·23]), outer membrane vesicle (OMV) vaccines against group B IMD (OR 0·35 [0·25-0·48]), and meningococcal ACWY (MenACWY) vaccines against group ACWY IMD (OR 0·31 [0·20-0·49]). A single time series analysis found a reduction following an infant 4CMenB program (incidence rate ratio, 0·25 [0·19-0·36]). Multivalent MenACWY vaccines did not reduce carriage (relative risk [RR] 0·88 [0·66-1·18]), unlike monovalent A (RR 0·73 [0·61-0·85]), and C vaccines (RR 0·50 [0·26-0·97]). 4CMenB vaccine had no effect on group B carriage (RR 1·12 [0·90-1·40]). There was also no reduction in group B carriage following MenB-FHbp vaccination (RR 0.98 [0.53-1.79]). Conclusions Meningococcal conjugate C, ACWY, and OMV vaccines are effective at reducing IMD. A small number of studies demonstrate that monovalent C and A conjugate vaccines reduce pharyngeal N. meningitidis carriage. There is no evidence of carriage reduction for multivalent MenACWY, OMV, or recombinant meningococcal B vaccines, which has implications for immunisation strategies. Registration PROSPERO CRD42018082085

scholarly journals Meningococcal Group B Vaccine For The Prevention Of Invasive Meningococcal Disease Caused By Neisseria meningitidis Serogroup B

2019 ◽  
Vol Volume 12 ◽  
pp. 3169-3188 ◽  
Author(s):  
Irene Rivero-Calle ◽  
Peter Francis Raguindin ◽  
Jose Gómez-Rial ◽  
Carmen Rodriguez-Tenreiro ◽  
Federico Martinón-Torres
Keyword(s):  
Neisseria Meningitidis ◽  
Meningococcal Disease ◽  
Invasive Meningococcal Disease ◽  
Meningococcal Group ◽  
Group B

scholarly journals Potential Capsule Switching from Serogroup Y to B: The Characterization of Three suchNeisseria meningitidisIsolates Causing Invasive Meningococcal Disease in Canada

2005 ◽  
Vol 16 (3) ◽  
pp. 171-174 ◽  
Author(s):  
Raymond SW Tsang ◽  
Dennis KS Law ◽  
Shaun D Tyler ◽  
Gwen S Stephens ◽  
Mark Bigham ◽  
...  
Keyword(s):  
Neisseria Meningitidis ◽  
Meningococcal Disease ◽  
Multilocus Sequence Typing ◽  
Housekeeping Gene ◽  
Sequence Type ◽  
Invasive Meningococcal Disease ◽  
Group B

Three group BNeisseria meningitidisisolates, recovered from meningococcal disease cases in Canada and typed as B:2c:P1.5, were characterized. Multilocus sequence typing showed that all three isolates were related because of an identical sequence type (ST) 573. Isolates typed as 2c:P1.5 are common in serogroup Y meningococci but rare in isolates from serogroups B or C. Although no serogroup Y isolates have been typed as ST-573, eight isolates showed five to six housekeeping gene alleles that were identical to that of ST-573. This suggested that the B:2c:P1.5 isolates may have originated from serogroup Y organisms, possibly by capsule switching.

scholarly journals Current Meningococcal Vaccines: Advantages and Disadvantages and New Challenges

2016 ◽  
Vol 15 (4) ◽  
pp. 64-73 ◽  
Author(s):  
N. N. Kostyukova ◽  
V. A. Bekhalo
Keyword(s):  
Neisseria Meningitidis ◽  
Meningococcal Disease ◽  
Invasive Meningococcal Disease ◽  
Reverse Vaccinology ◽  
Conjugate Vaccines ◽  
Meningococcal Vaccines ◽  
Advantages And Disadvantages ◽  
Vaccine Product ◽  
New Challenges ◽  
The Creation

The article reviews and analyses the vaccines against invasive meningococcal disease, widely used in practice since 70s-80s of the last century, as well as newly developed ones, the efficacy of which is not completely clear yet. The advantages and disadvantages of polysaccharide and glycoprotein vaccines against meningococci of serogroups A, C, Y, W135 and of protein «vesicle» and geneticengineering vaccines based on «reverse vaccinology» against serogroup B are discussed. Some options for composition of future vaccines under development are presented. Briefly the meningococcal vaccines used in Russia are described. Among the most important immediate tasks discussed are: the study of the duration and intensity of protection after immunization with conjugate vaccines; the development and subsequent trials of a vaccine against serogroup X; further study and improvement of vaccines against serogroup B, as well as the creation of a single vaccine product that protects against all antigenic variants of Neisseria meningitidis.

scholarly journals Culture-Confirmed Invasive Meningococcal Disease in Canada, 2010 to 2014: Characterization of Serogroup B Neisseria meningitidis Strains and Their Predicted Coverage by the 4CMenB Vaccine

mSphere ◽  
2020 ◽  
Vol 5 (2) ◽  
Author(s):  
Raymond S. W. Tsang ◽  
Dennis K. S. Law ◽  
Rosita De Paola ◽  
Maria Giuliani ◽  
Maria Stella ◽  
...  
Keyword(s):  
Molecular Epidemiology ◽  
Neisseria Meningitidis ◽  
Meningococcal Disease ◽  
Factor H ◽  
Invasive Meningococcal Disease ◽  
Effective Control ◽  
Atlantic Region ◽  
Content Type ◽  
Laboratory Surveillance ◽  
4Cmenb Vaccine

ABSTRACT The molecular epidemiology of culture-confirmed invasive meningococcal disease (IMD) in Canada from 2010 to 2014 was studied with an emphasis on serogroup B Neisseria meningitidis (MenB) isolates, including their predicted coverage by the 4CMenB vaccine. The mean annual incidence rates of culture confirmed IMD varied from 0.19/100,000 in Ontario to 0.50/100,000 in New Brunswick and 0.59/100,000 in Quebec. In both Quebec and Atlantic region, MenB was significantly more common than other serogroups, while in other provinces, both MenB and serogroup Y (MenY) were almost equally common. The majority of MenB cases (67.0%) were in those aged ≤24 years, while most MenC (75.0%) and MenY (69.6%) cases were in adults more than 24 years old. The 349 MenB isolates were grouped into 103 sequence types (STs), 90 of which belonged to 13 clonal complexes (CCs). A large number of 4CMenB antigen genes were found among the Canadian MenB, which is predicted to encode 50 factor H binding protein (fHbp) types, 40 NHBA types, and 55 PorA genotypes. Provinces and regions were found to have their own unique MenB STs. A meningococcal antigen typing system assay predicted an overall MenB coverage by 4CMenB to be 73.6%, with higher coverage predicted for the two most common STs: 100% for ST154 and 95.9% for ST269, leading to higher coverage in both the Atlantic region and Quebec. Higher coverage (81.4%) was also found for MenB recovered from persons aged 15 to 24 years, followed by strains from infants and children ≤4 years old (75.2%) and those aged 5 to 14 years (75.0%). IMPORTANCE Laboratory surveillance of invasive meningococcal disease (IMD) is important to our understanding of the evolving nature of the Neisseria meningitidis strain types causing the disease and the potential coverage of disease strains by the newly developed vaccines. This study examined the molecular epidemiology of culture-confirmed IMD cases in Canada by examining the strain types and the potential coverage of a newly licensed 4CMenB vaccine on Canadian serogroup B N. meningitidis strains. The strain types identified in different parts of Canada appeared to be unique as well as their predicted coverage by the 4CMenB vaccine. These data were compared to data obtained from previous studies done in Canada and elsewhere globally. For effective control of IMD, laboratory surveillance of this type was found to be essential and useful to understand the dynamic nature of this disease.

Prevalence and genetic diversity of two adhesion-related genes, pilE and nadA, in Neisseria meningitidis in China

2013 ◽  
Vol 141 (10) ◽  
pp. 2163-2172 ◽  
Author(s):  
X. SUN ◽  
H. ZHOU ◽  
L. XU ◽  
H. YANG ◽  
Y. GAO ◽  
...  
Keyword(s):  
Genetic Diversity ◽  
Neisseria Meningitidis ◽  
Adhesion Molecules ◽  
Meningococcal Disease ◽  
Class Ii ◽  
Type Iv Pili ◽  
Invasive Meningococcal Disease ◽  
Class I ◽  
Type Iv

SUMMARYThe main Neisseria meningitidis adhesion molecules, type IV pili (Tfp) and Neisseria adhesion A (NadA), play important roles in the pathogenesis of invasive meningococcal disease. PilE is the major Tfp subunit. In this study, the prevalence and genetic diversity of pilE and nadA were investigated in the prevalent serogroups and clonal complexes (CC) of N. meningitidis isolated in China. All serogroup A strains belonging to CC1 and CC5 and all CC11 serogroup W135 strains were clustered into class II PilE clades. All serogroup C and most of serogroup B isolates except CC8 and ST5642 were class I PilE clades. Class II pilE sequences were highly conserved. All isolates belonging to class I PilE isolates were nadA negative. However, nadA-positive strains were exclusively found in CC5 and CC11 isolates (class II PilE). This study showed that PilE and NadA may be related to epidemic or endemic meningococcal disease.

scholarly journals An outbreak of severe invasive meningococcal disease due to a capsular switched Neisseria meningitidis hypervirulent strain B:cc11

2019 ◽  
Vol 25 (1) ◽  
pp. 111.e1-111.e4 ◽  
Author(s):  
P. Stefanelli ◽  
C. Fazio ◽  
P. Vacca ◽  
A. Palmieri ◽  
L. Ambrosio ◽  
...  
Keyword(s):  
Neisseria Meningitidis ◽  
Meningococcal Disease ◽  
Invasive Meningococcal Disease
Sign in / Sign up

Export Citation Format

Share Document